Literature DB >> 8703661

Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients.

R S Miller1, G M Peterson, F Abbott, I Maddocks, D Parker, S McLean.   

Abstract

1. Plasma concentrations of fentanyl were measured by g.c. in 20 patients (median age: 75 years and range: 54-86 years; eight females) in palliative care receiving the drug by continuous s.c. infusion (median rate: 1200 micrograms day-1 and range: 100-5000 micrograms day-1). 2. The infusion rate was significantly related to the duration of therapy (Spearman rho = 0.56, P < 0.05). The total steady-state plasma concentrations of fentanyl ranged between 0.1 and 9 ng ml-1, with a median of 1 ng ml-1. The unbound fraction of fentanyl in the plasma ranged from 17.8 to 44.4%, with a median value of 33.6%. Infusion rates and both total and unbound plasma concentrations of fentanyl were correlated (Spearman rho = 0.92, P < 0.05 in each case). Even with standardization for dosage, there was an eightfold variation in total plasma concentrations and 3.5-fold variation in unbound plasma concentrations of fentanyl. 3. There is considerable inter-patient variability in the pharmacokinetics of fentanyl with s.c. infusion in the palliative care setting, which necessitates careful titration of dosage according to individual clinical response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8703661      PMCID: PMC1365210     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Syringe driver in terminal care.

Authors:  S B Dover
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-28

2.  Comparative pharmacokinetics of fentanyl and alfentanil.

Authors:  S Bower; C J Hull
Journal:  Br J Anaesth       Date:  1982-08       Impact factor: 9.166

3.  Plasma concentration and protein binding of alfentanil during high-dose infusion for cardiac surgery.

Authors:  M Hynynen; M Hynninen; H Soini; P J Neuvonen; J Heinonen
Journal:  Br J Anaesth       Date:  1994-05       Impact factor: 9.166

4.  Transdermal fentanyl for pain control in patients with cancer.

Authors:  Angela W Miser; Prem K Narang; Judith A Dothage; Robert C Young; William Sindelar; James S Miser
Journal:  Pain       Date:  1989-04       Impact factor: 6.961

Review 5.  Pharmacological management of cancer pain.

Authors:  S A Schug; R Dunlop; D Zech
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of fentanyl and its newer derivatives.

Authors:  L E Mather
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

7.  Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics.

Authors:  R K Portenoy; M A Southam; S K Gupta; J Lapin; M Layman; C E Inturrisi; K M Foley
Journal:  Anesthesiology       Date:  1993-01       Impact factor: 7.892

8.  Sensitive gas liquid chromatography method for the determination of fentanyl concentrations in blood.

Authors:  S R Kowalski; G K Gourlay; D A Cherry; C F McLean
Journal:  J Pharmacol Methods       Date:  1987-12

9.  Subcutaneous infusions for control of cancer symptoms.

Authors:  P Storey; H H Hill; R H St Louis; E E Tarver
Journal:  J Pain Symptom Manage       Date:  1990-02       Impact factor: 3.612

  9 in total
  2 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients.

Authors:  Astrid W Oosten; João A Abrantes; Siv Jönsson; Peter de Bruijn; Evelien J M Kuip; Amílcar Falcão; Carin C D van der Rijt; Ron H J Mathijssen
Journal:  Eur J Clin Pharmacol       Date:  2016-01-14       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.